CF
CERO

Cantor Fitzgerald’s CERo Therapeutics CERO Stock Holding History

Cantor Fitzgerald’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-78
Closed -$10K – 403
2024
Q4 		$10K Buy
+78
New +$18.2K ﹤0.01% 252
2024
Q1 		– Sell
-78
Closed -$2 – 337
2023
Q4 		$2 Hold
78
– – ﹤0.01% 252
2023
Q3 		$2 Hold
78
– – ﹤0.01% 551
2023
Q2 		$2 Hold
78
– – ﹤0.01% 568
2023
Q1 		$2 Buy
+78
New +$1.64M ﹤0.01% 668
2022
Q3 		– Sell
-375
Closed -$7.51M – 859
2022
Q2 		$7.51M Hold
375
– – 0.15% 193
2022
Q1 		$7.5M Hold
375
– – 0.57% 45
2021
Q4 		$7.43M Buy
+375
New +$7.44M 0.53% 40

Other funds holding CERO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Cantor Fitzgerald's CERO Position: Q1 2025 in Review

Cantor Fitzgerald sold out of CERo Therapeutics (CERO) in Q1 2025, closing a stake of 78 shares — an estimated $10K sold.

Cantor Fitzgerald first reported a position in CERO in Q4 2021 and held it in 8 quarters. The position peaked at $7.51M in Q2 2022. 13 funds tracked by Wall St. Rank hold CERO as of Q1 2025.

  • Cantor Fitzgerald reported no remaining CERo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 78 CERo Therapeutics shares in Q1 2025, an estimated $10K.
  • Cantor Fitzgerald first reported a position in CERo Therapeutics in Q4 2021 and held it in 8 quarters.
  • Cantor Fitzgerald's CERo Therapeutics position peaked at $7.51M in Q2 2022.
  • 13 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2025.

Based on Cantor Fitzgerald's 13F filing for Q1 2025, filed 15 May 2025.